Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Microbiotix

Next Previous
Drug Profile

Research programme: antibacterials - Microbiotix

Alternative Names: 259C; AcrAB-TolC efflux pump inhibitors - Microbiotix; Aminospectinomycins - Microbiotix; AU-FQ hybrids; bIAI compounds; bis-imidazolinylindole compound series; Fatty acid biosynthesis (FAB) pathway inhibitors - Microbiotix; GON X - Microbiotix; Inhibitors of DnaA initiator protein - Microbiotix; Inhibitors of initiation of DNA replication - Microbiotix; Inhibitors of wall teichoic acid (WTA) - Microbiotix; MBX 1158; MBX 1162; MBX 1196; MBX 1337; MBX 1339; MBX 1641; MBX 2319 analogues - Microbiotix; MBX 3132; MBX 3795; MBX 3796; MBX 3797; MBX 4191; MBX-500; Sortase A (SrtA) inhibitors for Gram-positive infections - Microbiotix; SOS induction inhibitors - Microbiotix; Spectinamide antibacterials for MDR/XDR tuberculosis - Microbiotix; Spectinomycin analogues - Microbiotix; T3SS inhibitors; TTSS inhibitors; Tuberculosis therapies - Microbiotix; VAP X- Microbiotix

Latest Information Update: 25 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Microbiotix
  • Developer GLSynthesis; Microbiotix
  • Class Acetamides; Amidines; Aminocyclitols; Antibacterials; Carboxylic acids; Coumarins; Heterocyclic compounds; Imidazoles; Indoles; Pyrans; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA helicase inhibitors; DNA helicase-primase inhibitors; DNA synthesis inhibitors; DNA-binding protein inhibitors; DNA-directed DNA polymerase inhibitors; Lipoteichoic acid inhibitors; Membrane protein inhibitors; Sortase A inhibitors; Toll-like receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Gonorrhoea; Pseudomonal infections
  • No development reported Bacterial infections; Gram-negative infections; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis

Most Recent Events

  • 25 Aug 2022 Early research in Pseudomonal-infections(Combination therapy, Prevention) is ongoing in USA (CARB-X pipeline, August 2022)
  • 28 Mar 2022 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
  • 28 Mar 2022 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top